top of page

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$22.7 M

Burn Rate (Qtr)

NA

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

CYAD

BPIQ_Logo_RGB-01.jpg

Company Profile

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors.

Recent Posts

See what the community is saying - click to see full post.

ASCO Gastrointestinal Cancers Symposium 2022

The American Society of Hematology Annual Meeting - Investor Hub 2021

Cancer Focused Smid-cap Biopharmas Presenting at SITC 2021 - Investor Hub

bottom of page